4Front Ventures Corp FFNTF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if FFNTF is a good fit for your portfolio.
News
-
4Front Ventures Announces Issuance of Securities to Consultants, Directors, and Officers
-
4Front Ventures Reports Fourth Quarter and Full Year 2023 Financial Results
-
4Front Ventures to Report Fourth Quarter and Full Year 2023 Financial Results on April 15, 2024
-
4Front Ventures Provides Progress Report on Norridge Opening and Matteson Facility Updates and Announces Launch of Crystal Clear Blast in Massachusetts and Illinois
-
4Front Ventures Unveils Mission: A Signature Cannabis Experience
-
4Front Furthers Expansion Strategy in Illinois
-
4Front Ventures Corp. Closes Transformational Senior Secured Debt to Equity Conversion
Trading Information
- Previous Close Price
- $0.09
- Day Range
- $0.08–0.10
- 52-Week Range
- $0.07–0.30
- Bid/Ask
- $0.08 / $0.11
- Market Cap
- $78.62 Mil
- Volume/Avg
- 140,442 / 348,688
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.57
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
4Front Ventures Corp is a Canadian-based company. It is engaged in the cultivation, processing, extracting, manufacturing, and distribution of cannabis products. It operates in two segments: THC Cannabis and CBD Wellness. The THC Cannabis segment engages in the production and cultivation of THC cannabis, manufacturing and distribution of cannabis products to owned dispensaries and third-party retail customers. The CBD Wellness segment encompasses the production and sale of CBD products to third-party customers.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 699
- Website
- https://www.4frontventures.com
Comparables
Valuation
|
Metric
|
FFNTF
|
CL
|
VRNO
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 1.43 | 1.34 |
Price/Sales | 0.57 | 0.88 | 1.73 |
Price/Cash Flow | — | 15.60 | 14.80 |
Price/Earnings
FFNTF
CL
VRNO
Financial Strength
|
Metric
|
FFNTF
|
CL
|
VRNO
|
|---|---|---|---|
Quick Ratio | 0.11 | 0.78 | 0.52 |
Current Ratio | 0.34 | 1.39 | 0.96 |
Interest Coverage | −4.76 | −1.36 | 1.46 |
Quick Ratio
FFNTF
CL
VRNO
Profitability
|
Metric
|
FFNTF
|
CL
|
VRNO
|
|---|---|---|---|
Return on Assets (Normalized) | −10.78% | −3.12% | −2.28% |
Return on Equity (Normalized) | — | −8.02% | −4.10% |
Return on Invested Capital (Normalized) | −11.21% | −0.11% | −0.53% |
Return on Assets
FFNTF
CL
VRNO
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Bhtqdhlmc | Sjqhnlz | $69.8 Bil | |
ZTS
| Zoetis Inc Class A | Fhtkrdhzb | Tbzyv | $68.9 Bil | |
HLN
| Haleon PLC ADR | Vddyrvchg | Vbff | $37.7 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Rfvssmvwz | Ckpp | $14.8 Bil | |
VTRS
| Viatris Inc | Mvwxccjj | Xlrg | $13.6 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Nmnmhgnxc | Ntnx | $11.9 Bil | |
CTLT
| Catalent Inc | Fqfdpxrwh | Myjqfr | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Kjzlxnl | Qjyh | $4.2 Bil | |
CURLF
| Curaleaf Holdings Inc | Pcynbdc | Nfhqq | $3.6 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Mxptdns | Ngnqpb | $3.5 Bil |